IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.

Karim Chamie,Sam S Chang, Eugene Kramolowsky,Mark L Gonzalgo,Piyush Kumar Agarwal,Jeffrey C Bassett,Marc Bjurlin,Michael L Cher,William Clark,Barrett E Cowan,Richard David, Evan Goldfischer,Khurshid Guru,Mark W Jalkut,Samuel D Kaffenberger, Jed Kaminetsky,Aaron E Katz, Alec S Koo,Wade J Sexton,Sergei N Tikhonenkov,Edouard J Trabulsi,Andrew F Trainer,Patricia Spilman,Megan Huang,Paul Bhar, Sharif A Taha,Lennie Sender,Sandeep Reddy,Patrick Soon-Shiong

NEJM Evidence（2022）

引用 6|浏览19

暂无评分

摘要

IL-15 Superagonist NAI in BCG-Unresponsive NMIBCIn this trial, patients with BCG-unresponsive bladder CIS with or without Ta/T1 papillary disease or BCG-unresponsive high-grade Ta/T1 papillary NMIBC were treated with intravesical NAI, an IL-15 superagonist, plus BCG. Primary end points were CR at 3 or 6 months for patients with CIS disease and DFS rate at 12 months for those with high-grade Ta/T1 disease. CR rate was 71% (58 of 82 patients), and the DFS rate was 55.4%.

查看译文

关键词

bladder cancer,bcg-unresponsive,muscle-invasive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要